Esprinet (PRT) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
17 Dec, 2025Executive summary
Achieved strong FY2024 results with adjusted EBITDA up 8% to €69.5M and gross sales up 6% to €4.4B, outperforming the IT market in EMEA and Southern Europe and regaining profitability.
Strengthened leadership in Southern Europe, expanded technology portfolio, and launched Zeliatech to drive digital and green transitions.
Demonstrated resilience and profitability despite complex geopolitical and economic challenges.
Reinstated/proposed dividend at €0.40 per share, reflecting improved financial stability and a payout ratio above 90%.
Financial highlights
Adjusted EBITDA reached €69.5M (+8% year-over-year); gross sales grew 6% to €4.4B; gross profit margin stable at 5.54%.
Adjusted EBIT was €46.2M (+5% year-over-year); net income improved to €21.5M from a €11.9M loss in 2023.
Net financial position at -€36.2M post-IFRS 16, mainly due to lease liabilities and tax payment plans.
Cash conversion cycle stabilized at 22 days, improving by 6 days year-over-year.
Net equity rose to €389.2M from €367.4M.
Outlook and guidance
2025 market expected to see low to mid single-digit growth, with PC refresh cycle and end of Windows 10 support driving demand.
EMEA AI spending forecasted to grow 35% in 2025; focus on AI, cloud, cybersecurity, and energy efficiency.
Focus remains on profitable growth, working capital optimization, and return on capital employed.
2025 guidance to be announced with Q1 results in May.
Latest events from Esprinet
- 5% sales growth, stable EBITDA, €0.35 dividend, and CEO transition planned for 2026.PRT
Q4 202513 Mar 2026 - Q2 2024 delivered 9% EBITDA growth, improved cash cycle, and market share gains in key segments.PRT
H1 202421 Jan 2026 - Q3 sales up 11% and margin resilience drive positive EBITDA guidance for 2024.PRT
Q3 202414 Jan 2026 - H1 2025 sales up 4%, profitability improved, and guidance targets upper-end EBITDA.PRT
Q2 202527 Dec 2025 - Sales up 4% to €2.89bn, EBITDA Adj. up 3%, guidance confirmed at upper end of €63–71m.PRT
Q3 202526 Nov 2025 - Q1 sales up 4% to €962.4M, but EBITDA Adjusted down 24% on higher costs.PRT
Q1 202519 Nov 2025